First MYA now NLS, page-5

Hi Zero,
in one way I think you can roughly estimate the bottom value of this company if you compare it to iSN
they have a mC of about 25m at the moment, much higher than us, but still a fraction of what it was when people thought the idea was still going to be successful. The ResApp tech is significantly superior in that it does not need a new device, will be much cheaper to produce ( and buy) have very large margins, be available to anyone not just those with enough money, targets a number of respiratory conditions (not just asthma), has significant developing world applications (making money and helping people whilst decreasing the problem of antibiotic resistance), can be incorporated in health plans easily so will have continued traction, will appeal to gov and health insurers as a way to decrease costs, could be used in home health monitoring of at risk patients (eg elderly, remote) etc, etc (Sunday morning-that is enough!).

One more thing. They have a successful clinical trial already done and supported by the gates foundation. Add to that a successful board it all adds up to a very good story to me.

please DYOR
cheers all